Sign Up for Free!

Continue Analyzing the page and more.

Already have an Account? Log In

The Trial has ended

Continue Analyzing the page and more.

Ticker Image

US$0

US$210.6b

-2.0%

46.8%

Overview Price History News Competitors Earnings per Share Return on Equity Net Margin Share Buyback Leverage Financial Ratio
Dashboard Funda..tals Deep..lue Prediction Screener Map

AstraZeneca PLC ADR Overview

Industry: Drug Manufacturers General

Sector: Healthcare

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Andexxa/Ondexxya, Atacand, Atacand HCT, Atacand Plus, Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, Xigduo/Xigduo, and Zestril XR for cardiovascular, renal, and metabolism diseases; Accolate, Accoleit, Vanticon, Bevespi Aerosphere, Breztri Aerosphere, Bricanyl Respules and Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Rhinocort, Saphnelo, Symbicort, and Tezspire for respiratory and immunology; and Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. Its marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; and Personalis, Inc. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom. AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for Read More

AstraZeneca PLC ADR is evaluated based on the investment philosophy and approach to stock market investing developed by renowned investor Warren Buffett. Companies with high ratings typically exhibit growing earnings, a substantial profit margin, conservative leverage, a consistently high return on equity, and a sustained practice of repurchasing their shares over the years.

AstraZeneca PLC ADR

Score

Recent News



Earnings Per Share

Score 3.00/5
AstraZeneca PLC ADR boasts a high score, as its Earnings Per Share (EPS) has demonstrated consistent growth over the past six years. Notable counterparts in the sector with high scores includes Agilent Technologies Inc Zoetis Inc IQVIA Holdings Inc
In Drug Manufacturers General industry , Amgen Inc , Johnson & Johnson , Gilead Sciences Inc are companies with high ratings.

Return on Equity

Score 1.84/5
AstraZeneca PLC ADR exhibits a lower score in the Return on Equity (ROE) section, falling below the sector median value and indicating a comparatively weaker performance in this metric. The top companies in the same sector include Agilent Technologies Inc Zoetis Inc IQVIA Holdings Inc

0% 10.0% 20.0% 30.0% 40.0%

ROE

Company 0%

SP500 Industry 0%

0% 10.0% 20.0% 30.0% 40.0%

ROE

Company 0%

SP500 Industry 0%

0% 10.0% 20.0% 30.0% 40.0%

ROE

Company 0%

SP500 Industry 0%

0% 10.0% 20.0% 30.0% 40.0%

ROE

Company 0%

SP500 Industry 0%

In Drug Manufacturers General industry , Amgen Inc , Johnson & Johnson , Gilead Sciences Inc are companies with high ratings.

0% 10.0% 20.0% 30.0% 40.0%

ROE

Company 0%

SP500 Industry 0%

0% 10.0% 20.0% 30.0% 40.0%

ROE

Company 0%

SP500 Industry 0%

0% 10.0% 20.0% 30.0% 40.0%

ROE

Company 0%

SP500 Industry 0%

0% 10.0% 20.0% 30.0% 40.0%

ROE

Company 0%

SP500 Industry 0%

Net Margin

Score 2.10/5
AstraZeneca PLC ADR olds a low score as its net margin consistently trails below the sector median value and doesn't exhibit continuous growth over the last six years; notable companies in the sector with commendable scores include Agilent Technologies Inc Zoetis Inc IQVIA Holdings Inc

0% 10.0% 20.0% 30.0% 40.0%

Net Margin

Company 0%

SP500 Industry 0%

0% 10.0% 20.0% 30.0% 40.0%

Net Margin

Company 0%

SP500 Industry 0%

0% 10.0% 20.0% 30.0% 40.0%

Net Margin

Company 0%

SP500 Industry 0%

0% 10.0% 20.0% 30.0% 40.0%

Net Margin

Company 0%

SP500 Industry 0%

In Drug Manufacturers General industry , Amgen Inc , Johnson & Johnson , Gilead Sciences Inc are companies with high ratings.

0% 10.0% 20.0% 30.0% 40.0%

Net Margin

Company 0%

SP500 Industry 0%

0% 10.0% 20.0% 30.0% 40.0%

Net Margin

Company 0%

SP500 Industry 0%

0% 10.0% 20.0% 30.0% 40.0%

Net Margin

Company 0%

SP500 Industry 0%

0% 10.0% 20.0% 30.0% 40.0%

Net Margin

Company 0%

SP500 Industry 0%

Share Buyback

In Drug Manufacturers General industry , Amgen Inc , Johnson & Johnson , Gilead Sciences Inc are companies with high ratings.

Leverage

Score 1.35/5
AstraZeneca PLC ADR registers a lower score in the category as a result of its elevated leverage ratio over the past six years compared to the sector median value. Conversely, other companies in the same sector, including Agilent Technologies Inc Zoetis Inc IQVIA Holdings Inc have achieved high scores.

0    10.0    20.0    30.0    40.0   

Leverage

Company 0

SP500 Industry 0

0    10.0    20.0    30.0    40.0   

Leverage

Company 0

SP500 Industry 0

0    10.0    20.0    30.0    40.0   

Leverage

Company 0

SP500 Industry 0

0    10.0    20.0    30.0    40.0   

Leverage

Company 0

SP500 Industry 0

In Drug Manufacturers General industry , Amgen Inc , Johnson & Johnson , Gilead Sciences Inc are companies with high ratings.

0    10.0    20.0    30.0    40.0   

Leverage

Company 0

SP500 Industry 0

0    10.0    20.0    30.0    40.0   

Leverage

Company 0

SP500 Industry 0

0    10.0    20.0    30.0    40.0   

Leverage

Company 0

SP500 Industry 0

0    10.0    20.0    30.0    40.0   

Leverage

Company 0

SP500 Industry 0

Financial Ratio

Yearly Quarterly

Financial
Profitability
Growth
Cash Flow
Financial Health
Efficiency Ratios

Ticker Image

AstraZeneca PLC ADR

US$0

US$210.6b

-2.0%

46.8%